Innate Pharma SA (IPHYF) — 6-K Filings

6-K Filings (50)

• Innate Pharma Files 6-K, Reports Press Release — Dec 22, 2025 Risk: low
  Innate Pharma SA filed a Form 6-K on December 22, 2025, reporting a press release dated December 22, 2025. The filing does not contain specific financial figure
• Innate Pharma Files 6-K, Reports Press Release — Dec 11, 2025 Risk: low
  Innate Pharma S.A. filed a Form 6-K on December 11, 2025, reporting a press release dated the same day. The filing indicates the company is a foreign private is
• Innate Pharma Files 6-K Report — Nov 28, 2025 Risk: low
  Innate Pharma SA filed a Form 6-K on November 28, 2025, reporting a press release dated November 28, 2025. The filing does not contain specific financial figure
• Innate Pharma Files 6-K with Press Release — Nov 17, 2025 Risk: low
  Innate Pharma S.A. filed a Form 6-K on November 17, 2025, reporting information as a foreign private issuer. The filing includes a press release dated November
• Innate Pharma Files Form 6-K — Nov 13, 2025 Risk: low
  On November 13, 2025, Innate Pharma S.A. filed a Form 6-K. This report is for a foreign private issuer and indicates that the company files annual reports under
• 6-K Filing — Nov 10, 2025
• 6-K Filing — Nov 5, 2025
• Innate Pharma Files 6-K Report — Oct 15, 2025 Risk: low
  On October 13, 2025, Innate Pharma S.A. filed a Form 6-K report with the SEC. This filing includes a press release dated October 14, 2025, as Exhibit 99.1. Inna
• Innate Pharma SA Files 6-K with Q2 2025 Financials — Sep 17, 2025 Risk: low
  Innate Pharma SA filed a 6-K report on September 17, 2025, detailing financial information as of June 30, 2025. The report includes data on ordinary and prefere
• Innate Pharma Files 6-K Report — Sep 15, 2025 Risk: low
  Innate Pharma SA filed a Form 6-K on September 15, 2025, reporting a press release dated September 15, 2025. The filing is for a foreign private issuer and indi
• Innate Pharma Files 6-K, Announces Press Release — Sep 10, 2025 Risk: low
  On September 10, 2025, Innate Pharma SA filed a Form 6-K, reporting a press release dated September 10, 2025. The filing does not contain specific financial fig
• Innate Pharma Files 6-K, Announces Press Release — Sep 2, 2025 Risk: low
  Innate Pharma S.A. filed a Form 6-K on September 2, 2025, reporting a press release dated the same day. The filing does not contain specific financial figures o
• Innate Pharma Files 6-K, Reports Press Release — Aug 4, 2025 Risk: low
  Innate Pharma S.A. filed a Form 6-K on August 4, 2025, reporting a press release dated August 4, 2025. The company, headquartered in Marseille, France, is a for
• Innate Pharma Files 6-K Report — Jul 29, 2025 Risk: low
  Innate Pharma SA filed a Form 6-K on July 29, 2025, reporting a press release dated July 29, 2025. The filing is a report of a foreign private issuer and indica
• Innate Pharma SA Files 6-K Report — Jul 7, 2025 Risk: low
  Innate Pharma SA filed a Form 6-K on July 7, 2025, reporting information as of July 4, 2025. The filing includes a press release dated July 4, 2025, as Exhibit
• Innate Pharma Files 6-K Report — Jun 17, 2025 Risk: low
  Innate Pharma SA filed a Form 6-K on June 17, 2025, reporting a press release dated the same day. The filing does not contain specific financial figures or oper
• Innate Pharma Files 6-K Report — Jun 13, 2025 Risk: low
  Innate Pharma SA filed a Form 6-K on June 13, 2025, reporting a press release dated the same day. The company is a French biotechnology firm specializing in bio
• Innate Pharma Files 6-K, Announces Press Release — May 27, 2025 Risk: low
  Innate Pharma SA filed a Form 6-K on May 27, 2025, reporting a press release dated the same day. The filing does not contain specific financial figures or opera
• Innate Pharma Files 6-K, Announces Press Release — May 23, 2025 Risk: low
  Innate Pharma SA filed a Form 6-K on May 23, 2025, reporting a press release dated the same day. The filing does not contain specific financial figures or opera
• Innate Pharma Files 6-K Report — May 19, 2025 Risk: low
  On May 19, 2025, Innate Pharma SA filed a Form 6-K, reporting a press release dated May 19, 2025. The company, based in Marseille, France, is a biopharmaceutica
• Innate Pharma Files 6-K Report — May 15, 2025 Risk: low
  Innate Pharma SA filed a Form 6-K on May 15, 2025, reporting a press release dated the same day. The filing does not contain specific financial figures or opera
• Innate Pharma Files 6-K Report — May 13, 2025 Risk: low
  Innate Pharma S.A. filed a Form 6-K on May 13, 2025, reporting information as a foreign private issuer. The filing includes a reference to Exhibit 99.1, which i
• Innate Pharma Files 6-K Report — May 12, 2025 Risk: low
  Innate Pharma SA filed a Form 6-K on May 12, 2025, reporting a press release dated the same day. The filing does not contain specific financial figures or opera
• Innate Pharma Files 6-K, Announces Press Release — May 6, 2025 Risk: low
  Innate Pharma SA filed a Form 6-K on May 6, 2025, reporting a press release dated the same day. The filing does not contain specific financial figures or operat
• Innate Pharma Files 6-K Report with Press Release — Apr 29, 2025 Risk: low
  On April 29, 2025, Innate Pharma SA filed a Form 6-K report. This filing includes a press release dated April 29, 2025, as Exhibit 99.1. The company is a foreig
• Innate Pharma Files 6-K, Announces Press Release — Apr 28, 2025 Risk: low
  Innate Pharma SA filed a Form 6-K on April 28, 2025, reporting a press release dated the same day. The filing does not contain specific financial figures or ope
• Innate Pharma 6-K Filing Incorporates by Reference — Apr 24, 2025 Risk: low
  Innate Pharma S.A. filed a Form 6-K on April 24, 2025, to incorporate by reference information into its Form F-3 registration statement (File No. 333-276164). T
• Innate Pharma 6-K Filing Incorporates Exhibit into F-3 — Apr 23, 2025 Risk: low
  On April 23, 2025, Innate Pharma SA filed a Form 6-K. This report incorporates by reference Exhibit 99.1 into its Form F-3 registration statement (File No. 333-
• Innate Pharma Files 6-K Report — Apr 16, 2025 Risk: low
  Innate Pharma SA filed a Form 6-K on April 16, 2025, reporting information as of that date. The filing is for a foreign private issuer and indicates that the co
• Innate Pharma Files 6-K Report — Apr 3, 2025 Risk: low
  Innate Pharma SA filed a Form 6-K on April 3, 2025, reporting a press release dated the same day. The company, based in Marseille, France, is a biopharmaceutica
• Innate Pharma Files 6-K Report — Mar 27, 2025 Risk: low
  Innate Pharma S.A. filed a Form 6-K on March 27, 2025, reporting information as of that date. The filing is for a foreign private issuer and indicates that the
• Innate Pharma Files 6-K Report with Press Release — Mar 26, 2025 Risk: low
  On March 26, 2025, Innate Pharma SA filed a Form 6-K report. This filing includes a press release dated March 26, 2025, as Exhibit 99.1. The company is a foreig
• Innate Pharma Files 6-K Report with Press Release — Mar 25, 2025 Risk: low
  On March 25, 2025, Innate Pharma SA filed a Form 6-K report. This filing includes a press release dated March 25, 2025, as Exhibit 99.1. The company is a foreig
• Innate Pharma Files 6-K, Reports Press Release — Mar 20, 2025 Risk: low
  Innate Pharma SA filed a Form 6-K on March 20, 2025, reporting a press release dated March 20, 2025. The filing does not contain specific financial figures or o
• Innate Pharma Files 6-K — Feb 27, 2025 Risk: low
  Innate Pharma SA filed a Form 6-K on February 27, 2025, reporting a press release dated the same day. The filing does not contain specific financial figures or
• Innate Pharma 6-K Filing Incorporates into F-3 and S-8 Registrations — Feb 18, 2025 Risk: low
  Innate Pharma S.A. filed a Form 6-K on February 18, 2025, reporting information as of February 17, 2025. The filing incorporates by reference into existing regi
• Innate Pharma Files 6-K with Exhibit 99.1 — Jan 27, 2025 Risk: low
  Innate Pharma S.A. filed a Form 6-K on January 27, 2025, reporting information as a foreign private issuer. The filing includes Exhibit 99.1, which contains sta
• Innate Pharma Files 6-K, Announces Press Release — Jan 21, 2025 Risk: low
  Innate Pharma SA filed a Form 6-K on January 21, 2025, reporting a press release dated the same day. The filing does not contain specific financial figures or o
• Innate Pharma Files 6-K, Cites CEO on J.P. Morgan Conference — Jan 16, 2025 Risk: low
  Innate Pharma S.A. filed a Form 6-K on January 16, 2025, reporting information as of that date. The filing is for a foreign private issuer and indicates that th
• Innate Pharma Files 6-K, Mentions J.P. Morgan Conference — Jan 10, 2025 Risk: low
  Innate Pharma S.A. filed a Form 6-K on January 10, 2025, reporting on its activities. The filing references its participation in the 43rd Annual J.P. Morgan Hea
• Innate Pharma Files 6-K Report — Dec 20, 2024 Risk: low
  Innate Pharma SA filed a Form 6-K on December 20, 2024, reporting a press release dated the same day. The filing does not contain specific financial figures or
• Innate Pharma Files 6-K Report — Dec 9, 2024 Risk: low
  Innate Pharma SA filed a Form 6-K on December 9, 2024, reporting a press release dated the same day. The filing does not contain specific financial figures or o
• Innate Pharma Files 6-K Report — Dec 6, 2024 Risk: low
  Innate Pharma S.A. filed a Form 6-K on December 6, 2024, reporting on its activities. The filing includes information about the company's principal executive of
• Innate Pharma Files 6-K Report — Dec 3, 2024 Risk: low
  Innate Pharma SA filed a Form 6-K on December 3, 2024, reporting a press release dated the same day. The filing does not contain specific financial figures or o
• Innate Pharma Files 6-K, Issues Press Release — Nov 20, 2024 Risk: low
  Innate Pharma S.A. filed a Form 6-K on November 20, 2024, to report a press release dated the same day. The filing does not contain specific financial figures o
• Innate Pharma Files 6-K Report — Nov 19, 2024 Risk: low
  Innate Pharma SA filed a Form 6-K on November 19, 2024, to report a press release dated the same day. The filing does not contain specific financial figures or
• Innate Pharma Files 6-K Report — Nov 13, 2024 Risk: low
  Innate Pharma S.A. filed a Form 6-K on November 13, 2024, reporting information as of the same date. The filing is a report of a foreign private issuer and indi
• Innate Pharma Files 6-K Report — Nov 8, 2024 Risk: low
  Innate Pharma SA filed a Form 6-K on November 8, 2024, to report a press release dated the same day. The filing itself does not contain detailed financial infor
• Innate Pharma Files 6-K Report — Nov 7, 2024 Risk: low
  On November 7, 2024, Innate Pharma S.A. filed a Form 6-K report with the SEC. This filing includes a press release dated November 7, 2024, which is the primary
• Innate Pharma Files 6-K, Names New CEO — Oct 29, 2024 Risk: low
  Innate Pharma S.A. filed a Form 6-K on October 29, 2024, reporting information as of that date. The filing includes details about the company's principal execut

Popular Companies

AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX